The Blood Clot Preventive Drugs Market is expected to grow by leaps and bounds in the forecast period. Nanotechnology’s medical application is on the anvil. As such, nanomedicine is an outcome of the technology operating at the molecular, atomic, or supramolecular scale. The broad application areas of nanomedicine include sensing, imaging, diagnosis, and delivery via medical devices. This would certainly keep the healthcare vertical upgraded continuously.
According to CDC statistics, approx. 60,000-100,000 American’s die of venous thromboembolism conditions and 0.9 Million population affected each year in the United States. In Europe, every year approx. 544,000 die due to venous thromboembolism. To prevent blood clots, various treatment options are available in the market to treat these conditions. However, current drugs cause life-threatening side effects such as cerebral hemorrhages and neurotoxicity. To overcome the aforementioned problems companies are developing novel therapeutic agents to enhance fibrinolysis conditions. For instance, Daiichi Sankyo Company, Limited announced granted EU approval for its novel oral anticoagulant drug edoxaban used to prevent stroke and systemic embolism conditions in patients with non-valvular atrial fibrillation.
Request for Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/14302
The increase in incidence of venous thromboembolism conditions, the rise in obese population, myocardial infractions, stroke, pulmonary embolism and genetically related disorders are the factors driving the growth of this market over the forecast period. However, due to lack of awareness about venous thromboembolism conditions, side-effects caused due to current drugs are hindering the growth of blood clot prevention over the forecast period.
Globally the blood clot prevention market is divided into following:
Based on drug class, the global blood clot prevention market is divided into following
- Anticoagulants
- Heparin
- Warfarin
- Low Molecular Weight Heparin
- Enoxaparin
- Dalteparin
- Newer drugs
- Bivalirudin
- Fondaparinux
- Lepirudin
- Rivaroxaban
- Apixaban
- Fibrinolytics
- Streptokinase
- Urokinase
- Alteplase
- Reteplase
- Tenectlase
- Anti-Platelet Drugs
- Aspirin
- Ticlopidine
- Clopidogrel
- Abciximab
- Eptifibatide
Based on route of administration, the global blood clot prevention market is divided into following
- Oral Route
- Parenteral Route
Based on end user, the global blood clot prevention market is divided into following
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Mail order Pharmacies
The launch of novel therapeutic drugs to prevent blood clots in various blood vessels is expected to boost the growth of the market over the forecast period. Based on drug class it is segmented into anticoagulants, fibrinolytic and anti-platelet drugs. Anticoagulants segment is expected to dominate the market due to many of the drugs are off-patented.
If you have any query, ask the analyst @ https://www.persistencemarketresearch.com/ask-an-expert/14302
By route of administration, global blood clot prevention market is segmented into the oral route and parenteral route. Parenteral route dominates the market over the forecast period owing to availability drugs in parenteral formulation
Based on the distribution channel, global blood clot prevention market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and mail order pharmacies. Among them, hospital pharmacies are projected to have the highest market share over the forecast period.
Depending on the geographic region, blood clot prevention market is segmented into five key regions: North America, Latin America, Europe, Asia-Pacific and Middle East & Africa. North America is expected to have highest revenue share in blood clot prevention market owing to the high incidence of venous thromboembolism and deaths due to venous thromboembolism. Asia Pacific geography is expected to dominate the market in near future
Some of the key players in blood clot prevention market are Daiichi Sankyo Company, Limited, Janssen Pharmaceutical, Pfizer Inc., Bayer, Boehringer Ingelheim GmbH, Bristol- Meyers Squibb and Portola Pharmaceuticals
Pre-Book Right Now for Exclusive Analyst Support @ https://www.persistencemarketresearch.com/checkout/14302
About us: Persistence Market Research
Contact us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com